BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270127
DTEND;VALUE=DATE:20270130
DTSTAMP:20261028T115938Z
CREATED:20261028T115938Z
LAST-MODIFIED:20261028T115938Z
UID:44631-1801008000-1801267199@www.pharmajournalist.com
SUMMARY:8th RNAi-Based Therapeutics Summit
DESCRIPTION:The 8th RNAi-Based Therapeutics Summit returns to Boston from January 27-29\, 2027\, bringing together more than 90 industry experts working across oligonucleotide synthesis\, chemistry\, biology\, molecular design\, targeted delivery\, translational development\, and commercialization. The meeting will provide a focused forum for advancing safer\, more potent RNAi therapeutics and expanding their reach beyond traditional liver-directed applications. \nAs investment\, partnerships\, and clinical progress continue to build confidence in RNAi\, extrahepatic delivery remains one of the field’s most significant challenges. The summit will explore how next-generation delivery technologies and oligonucleotide chemistries can improve targeting selectivity\, potency\, durability\, pharmacokinetics\, pharmacodynamics\, and therapeutic index across neurology\, metabolic disease\, obesity\, cardiovascular disease\, kidney disease\, retinal disorders\, oncology\, and other high-value indications. \nAttendees will hear the latest developments in antibody-oligonucleotide conjugates\, aptamer-siRNA conjugates\, nanoparticles\, tetravalent siRNAs\, bispecific RNAi approaches\, cell-specific delivery\, and multi-target silencing strategies. Scientific presentations and panel discussions will examine how developers can cross the blood-brain barrier\, target skeletal muscle and adipose tissue\, deliver genetic medicines to the kidney\, improve retinal gene silencing\, and address complex tumor biology. \nTwo interactive pre-conference workshops will focus on identifying and validating receptors for selective extrahepatic delivery and modifying oligonucleotide chemistry to improve stability\, circulation time\, tissue exposure\, and PK/PD performance. The wider program will also address safety\, clinical translation\, commercialization\, investment\, and strategic partnerships\, helping developers progress promising candidates while reducing technical and commercial risk. \nFeaturing experts from organizations including Sanegene Bio\, Thalia Therapeutics\, Eli Lilly and Company\, Novo\, Bayer\, Bonito Biosciences\, Valaya Bio\, Judo Bio\, UMass Chan Medical School\, and Trinetra Therapeutics\, the summit offers an intimate environment for scientific exchange and meaningful collaboration. Attendees will leave with practical insights and valuable connections to support the development of the next generation of RNAi medicines. \nTo know more visit: https://ter.li/ger5rzdy
URL:https://www.pharmajournalist.com/event/8th-rnai-based-therapeutics-summit/
LOCATION:Homewood Suites by Hilton Boston Seaport District\, 670 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR